• Canadian Myeloma Research Group

  • Making future myeloma treatment available to
    Canadian patient today

  • Bringing More Clinical Trials, to More Patients,
    in More CentresAcross Canada

Our Research

Clinical Trials

Full Range of Clinical Trial Management

National Database

Leading Real-World Evidence Generation in Myeloma

National Biobank

Supporting Research In Myeloma


Transform myeloma research in Canada to accelerate cure


Develop and conduct innovative Phase I-III clinical trials and translational research in a collaborative manner aimed at improving patient outcomes in multiple myeloma and related diseases

Develop a correlative research platform supported by a national Biobank to advance the translational research capacity

Develop a national Multiple Myeloma database to position CMRG as a leader in Real World Data research and understand treatment patterns of myeloma patients in Canada

Publish evidence-based and peer reviewed consensus statements on the diagnosis and treatment of myeloma

The Network

CMRG infrastructure brings together centers of excellence across Canada to collaborate in designing future of myeloma research. CMRG plans to expand its membership from the centres 11 to 30 centres in 2019.


Download the Map Image here

Advantages and benefits

CMRG was established to facilitate accelerated start -up, rapid recruitment and cost-effective, clinically-relevant trials in Canada.

The CMRG advantages Include:

  • Accelerated start-up
  • Rapid accrual
  • Cost effective management
  • Quality of results
  • One-stop access to Canada’s network of myeloma investigators and academic centres
  • Proven track record
  • Collaboration with international experts
  • Patient-centric research

CMRG’s clinical trial portfolio continues to grow as a result of the advantages CMRG offers to both academic and Industry partners.

With the launch of the CMRG National Database, we will now be able to better gather patient outcome data from across the country to identify the optimal treatment approaches, using real-world evidence.

The national database will also help support public funding decisions with real-world data that will provide compelling clinical evidence to confirm the superiority of a novel treatment or combination.

Ultimately, research conducted in this collaborative, entrepreneurial setting promotes the advancement of clinical research and dissemination of results at an accelerated pace in Canada

Network Expertise

High-risk disease
Minimal residual disease .Mechanisms of resistance .Cell therapy
Drug target evaluation